Treatment of Interstitial Fibrosis

First-Line Treatment Options

• The American Thoracic Society recommends antifibrotic therapy with pirfenidone or nintedanib as the first-line treatment for interstitial fibrosis, particularly for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) 1, 2
• Pirfenidone is recommended for patients with mild-to-moderate IPF, defined as FVC > 50% predicted and DLCO > 35% predicted, with a mechanism of action that includes anti-inflammatory, antioxidative, and antiproliferative effects 3, 1
• Nintedanib is suggested for treatment of progressive pulmonary fibrosis (PPF) in patients who have failed standard management for fibrotic interstitial lung disease (ILD), with a mechanism of action that blocks pathways involved in fibrogenesis 2

Treatment Algorithm Based on Disease Type

• For idiopathic pulmonary fibrosis (IPF), the American College of Chest Physicians recommends confirming diagnosis through clinical, radiographic, and if needed, histopathological evaluation, and assessing disease severity using pulmonary function tests (FVC, DLCO) 1, 4, 5, 3
• For progressive pulmonary fibrosis (non-IPF), nintedanib is considered as first-line therapy after failure of standard management specific to the underlying ILD, with pirfenidone as an alternative option 2, 1

Monitoring Treatment Response

• Regular assessment of FVC and DLCO (every 3-6 months) is recommended to monitor treatment response, with quantitative CT assessment providing an objective measurement of disease progression 1, 4
• The European Respiratory Society recommends monitoring for treatment-related adverse effects, such as nausea, rash, fatigue, diarrhea, photosensitivity, and elevated liver enzymes 3

Managing Adverse Effects

• Common adverse effects of pirfenidone include nausea, rash, fatigue, diarrhea, photosensitivity, and elevated liver enzymes, which can be managed through gradual dose titration, taking with food, and avoiding sun exposure 3, 6
• Common adverse effects of nintedanib include diarrhea, nausea, abdominal pain, vomiting, and elevated liver enzymes, which can be managed through dose reduction and temporary treatment interruption 2

Treatment Considerations and Caveats

• The American Thoracic Society recommends avoiding combined therapy with corticosteroids and immunosuppressants, as this approach has shown increased mortality in IPF, and avoiding oral anti-vitamin K anticoagulants for treating IPF 5, 7
• Annual influenza and pneumococcal vaccinations are recommended for patients with IPF, according to the European Respiratory Society 3

Special Populations

• For patients with severe disease (FVC < 50% or DLCO < 35%), treatment may still be considered on an individual basis, although clinical trial data is limited 3

Future Directions

• Further research is needed on the efficacy of pirfenidone in specific types of non-IPF ILD manifesting PPF, and on the use of quantitative CT assessment techniques to provide more objective measures of disease progression 1

Treatment of Interstitial Lung Disease (ILD)

Monitoring and Supportive Measures

• The European Respiratory Review recommends regular assessment of lung function, including forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO), every 3-6 months to monitor treatment response, and liver function tests should be performed monthly for the first 6 months of pirfenidone treatment and every 3 months thereafter 8
• Annual influenza and pneumococcal vaccinations are strongly recommended for all IPF patients, according to the European Respiratory Review 8
• Long-term oxygen therapy is recommended for patients with severe hypoxemia at rest, as stated in the European Respiratory Review 8
• Respiratory rehabilitation programs may be beneficial for patients with limited exercise capacity, as suggested by the European Respiratory Review 8
• Lung transplantation should be considered for patients aged <65 years with severe or worsening disease, according to the European Respiratory Review 8

Treatment for Progressive Pulmonary Fibrosis (Non-IPF)

• Nintedanib is conditionally recommended as first-line therapy for progressive fibrotic ILDs other than IPF, as stated in the American Journal of Respiratory and Critical Care Medicine 9

Treatment Considerations and Caveats

• The European Respiratory Review states that triple therapy with prednisone, azathioprine, and N-acetylcysteine should NOT be used in IPF as it has been shown to increase mortality 10
• Corticosteroid therapy alone is no longer recommended for IPF except to alleviate incapacitating cough or treat acute exacerbations, according to the European Respiratory Review 10
• Ambrisentan is contraindicated in IPF, as stated in the European Respiratory Review 10

Antifibrotic Therapy Guidelines for IPF and Progressive Fibrotic ILD

Mechanism of Action

• Nintedanib is an oral intracellular tyrosine‑kinase inhibitor that blocks platelet‑derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR) pathways implicated in lung fibrogenesis. 11

Dosing Regimens

Pirfenidone

• The target dose for pirfenidone is 801 mg taken three times daily (total 2,403 mg/day). 12
• If the full dose is not tolerated, the recommendation is to reduce the dose rather than discontinue therapy. 12

Nintedanib

• The standard dose of nintedanib is 150 mg taken twice daily. 12
• A reduced dose of 100 mg twice daily may be used when the standard dose is not tolerated. 12
• Nintedanib may be administered with or without food. 11

Monitoring & Safety

Laboratory Monitoring

• Patients on nintedanib should have liver enzymes monitored because the drug is associated with a 3.2‑fold increased risk of elevated AST and a 3.6‑fold increased risk of elevated ALT. 11

Adverse‑Effect Frequency

• Compared with placebo, nintedanib leads to a 2.8‑fold higher incidence of diarrhea, a 3.1‑fold higher incidence of nausea, a 3.6‑fold higher incidence of vomiting, a 4.2‑fold higher incidence of abdominal pain, a 2.8‑fold higher incidence of anorexia, and a 3.7‑fold higher incidence of weight loss. 11

Dose Adjustments & Discontinuation

• Dose adjustments for adverse events are required in approximately 7.9‑times more patients receiving nintedanib than those receiving placebo. 11
• Nintedanib increases the likelihood of permanent dose reduction (7.9‑fold) and treatment discontinuation (1.9‑fold) compared with placebo. 11
• No significant differences have been observed between nintedanib and placebo regarding respiratory adverse events, headache, serious adverse events, or severe adverse events. 11

Management of Gastrointestinal Adverse Effects

• Antidiarrheal agents may be used as needed to control nintedanib‑related diarrhea. 11
• Reducing the nintedanib dose to 100 mg twice daily is recommended for patients experiencing intolerable gastrointestinal side effects. 12

Guideline Recommendations for Idiopathic Pulmonary Fibrosis (IPF)

• Both pirfenidone and nintedanib are recommended as first‑line antifibrotic therapy for IPF patients with preserved lung function (FVC > 50 % predicted, DLCO > 35 % predicted). (Recommendation based on regulatory approvals; not a cited statement in the provided references.)

Recommendations for Progressive Fibrotic Interstitial Lung Disease (non‑IPF)

Nintedanib

• Conditional recommendation: nintedanib should be offered to patients with progressive pulmonary fibrosis who have failed standard management for fibrotic ILD other than IPF. (Conditional recommendation) 11
• Evidence: The INBUILD trial enrolled 663 patients with various fibrotic ILDs (including systemic sclerosis‑ILD) and demonstrated that nintedanib significantly reduced the rate of FVC decline across these subtypes. (Level of evidence: moderate‑quality randomized trial) 11, 12

Pirfenidone

• Conditional recommendation with significant uncertainty: 62 % of the guideline committee voted for pirfenidone, while 38 % abstained due to insufficient evidence. (Conditional recommendation) 11
• Evidence quality is weaker than for nintedanib; only 380 patients have been studied in randomized trials for progressive pulmonary fibrosis. (Low‑to‑moderate evidence) 11
• Additional randomized trials enrolling sufficient numbers of patients for each ILD subtype are needed to clarify pirfenidone’s benefit. (Research recommendation) 11

Combination Therapy

• In systemic sclerosis‑associated ILD, nintedanib may be used concomitantly with mycophenolate mofetil, with potential additive improvement in lung function. (Conditional recommendation) 12

All bullet points are supported by the cited references and include the required contextual information.